Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders Gastrointestinal (GI) and hepatobiliary disorders affect the structure and function of the GI tract. Many of these disorder

Rosenthal, L. D., & Burchum, J. R. (2018). Lehne’s pharmacotherapeutics for advanced practice providers. St. Louis, MO: Elsevier.

• Chapter 62, “Drugs for Peptic Ulcer Disease” (pp. 703–714)

• Chapter 63, “Laxatives” (pp. 715–722)

• Chapter 64, “Other Gastrointestinal Drugs” (pp. 723–735)

• Chapter 78, “Antiviral Agents I: Drugs for Non-HIV Viral Infections” (pp. 867–886)

Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., . . . Sanya, A. J. (2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 67(1), 328–357. Retrieved from https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.29367

This article details the diagnosis and management of nonalcoholic fatty liver disease. Review this article to gain an understanding of the underlying pathophysiology as well as the suggested pharmacotherapeutics that might be recommended to treat this disorder.